Searchable abstracts of presentations at key conferences in endocrinology

Endocrine Abstracts

Published by BioScientifica
Previous issue | Volume 47 | Theranostics2016 | Next issue

4th Theranostics World Congress

4th Theranostics World Congress 2016

Spotlight on Neuroendocrine tumours

Previous section
Oral Speaker Communications
Table of contents
Next section
Spotlight on Prostate Cancer

ea0047oc1 | Spotlight on Neuroendocrine tumours

Integrating cancer genomics with imaging

ea0047oc2 | Spotlight on Neuroendocrine tumours

Production of Ga-68 radiotracers under GMP and regulatory aspects – a German perspective

ea0047oc3 | Spotlight on Neuroendocrine tumours

Optimised production of 64Cu-SARTATE for a phase 1 clinical trial

ea0047oc4 | Spotlight on Neuroendocrine tumours

68Ga, 64Cu labelling and affinity study of NODAGANOC, a NODAGA conjugated somatostatin analogue

ea0047oc5 | Spotlight on Neuroendocrine tumours

Influence of the radiopharmaceutical affinity and peptide content on the pharmacokinetics: [68Ga]Ga-DOTATOC and [68Ga]Ga-DOTATATE

ea0047oc6 | Spotlight on Neuroendocrine tumours

DNA damage assay in blood lymphocytes in peptide receptor radionuclide therapy patients with personalised high activities

ea0047oc7 | Spotlight on Neuroendocrine tumours

Two Decades of THERANOSTICS in Neuroendocrine Tumors – Past, Presence and Future of Peptide Receptor Radionuclide Therapy (PRRT)

ea0047oc8 | Spotlight on Neuroendocrine tumours

NETTER-1 Phase III in Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-Dotatate: Efficacy, Safety, QoL Results and Subgroup Analysis

ea0047oc9 | Spotlight on Neuroendocrine tumours

Clinical Perspective: The ‘difficult development situation’: how to approach and overcome challenges from a regulatory perspective

ea0047oc10 | Spotlight on Neuroendocrine tumours

The Cruel Wait for PRRT

ea0047oc11 | Spotlight on Neuroendocrine tumours

The challenges of waiting for RCTs vs treating patient’s now

ea0047oc12 | Spotlight on Neuroendocrine tumours

PET/CT based dosimetry for 90Y-DOTATOC treatment of neuroendocrine cancer

ea0047oc13 | Spotlight on Neuroendocrine tumours

Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumors: a simulation study

ea0047oc14 | Spotlight on Neuroendocrine tumours

68Ga-Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors – a head-to-head comparison with DOTATOC and FDG PET/CT

ea0047oc15 | Spotlight on Neuroendocrine tumours

Evaluation of somatostatin, CXCR4 chemokine and endothelin a receptor expression in a large series of paragangliomas

ea0047oc16 | Spotlight on Neuroendocrine tumours

Benefits and challenges of translating pre-clinical studies into clinical practice

ea0047oc17 | Spotlight on Neuroendocrine tumours

Dosimetry in 177Lu treatment: what we know and what we do not know

Published by BioScientifica

Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2025 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more